IV Simpósio Internacional de Oncologia Cutânea

DATA: 11 e 12 de março de 2022

Evento híbrido

Vagas limitadas: 100 pessoas

Apresentação: O curso aborda as diferentes facetas do cuidado de pacientes com neoplasias cutâneas a partir dos pilares que sustentam o cuidado centralizado no paciente, incluindo multidisciplinaridade, cooperação entre equipes e especialização.

Público-alvo: Dermatologistas, oncologistas clínicos, rádio oncologistas e cirurgiões oncológicos, além de acadêmicos e profissionais de saúde interessados no diagnóstico e no tratamento dos tumores cutâneos.

Comitê Científico: Núcleo de Tumores Cutâneos e Sarcomas do Hospital Sírio Libanês (Group of Cutaneous Malignancies and Sarcomas – Hospital Sírio Libanês)
Núcleo de Oncologia Cutânea e Sarcomas do Hospital Sírio Libanês (Group of Cutaneous Malignancies and Sarcomas – Hospital Sírio Libanês)
Centro de Oncologia do Hospital Sírio Libanês (Oncology Center – Hospital Sírio Libanês)
Núcleo de Dermatologia do Hospital Sírio Libanês (Dermatology Service – Hospital Sírio Libanês

Inscrições

Principais temas:IV Simpósio Internacional de Oncologia Cutânea

• Revisiting the evidences and alternatives for photoprotection
• Current status of melanoma screening – are we overdiagnosing in situ melanoma?
• The role of molecular pathology in differentiating pigmented lesions
• Dermatology insights: how not to miss the diagnosis of a melanoma?
• Integrating non-invasive techniques in the diagnosis of melanocytic lesions
• Sentinel LN biopsy in melanoma of the scalp/head and neck – controversies and recommendations
• Intralesional therapies in melanoma – updates and perspectives
• Tips and tricks for the appropriate management of lentigo
• Current adjuvant treatment options for high-risk stage II melanoma and future perspectives
• Debate: Now that we can treat high-risk stage II melanoma, should we perform SLN biopsy for this patient population? Yes vs No
• Stage III melanoma – shoot first and ask later?
• Current status of the first-line treatment in advanced melanoma
• Optimizing the benefit from ICP: DOs andDON’Ts
• Debate: oligometastatic melanoma – surgery first vs systemic treatment first
• Treatment beyond progression to first-line therapy in melanoma: what choices do we have?
• Tackling the microbiome: where are we?
• Ophthalmology: when to suspect and how to diagnose ocular malignancies?
• Geriatric medicine: geriatric assessment in the treatment of patients with skin cancer – weighing risks and benefits in the elderly population?
• Endocrinology: Vitamin D, sun exposure and skin cancers – myths and facts
• Alternatives beyond steroids in cutaneous immune-related adverse events
• Dermoscopy algorithms in challenging skin tumors
• Treatment duration in patients with advanced cutaneous malignancies receiving ICP - does one size fit all?
• Surgery with microscopically controlled margins – current status in melanoma, BCC and SCC
• When a patient with skin cancer should seek genetic counseling?
• Current indications for RT in skin cancers
• Debate: will AI replace the dermatologist? Yes vs No
• Systemic therapies in immunocompromised patients and transplant recipients
• Approach to field cancerization in the immunocompromised patient
• Dermatologic monitoring and follow of the immunocompromised patient
• What is the optimal treatment for patients with MCC with and without nodal involvement?
• Advances in systemic treatments over the past years
• Initial approach and what to avoid?
• Treatment algorithms for patients with advanced disease
• Revisiting the risk factors and risk stratification for SCC
• Current indications of systemic therapies in SCC
• Non-surgical approaches to keratinocyte carcinomas: when and how?





Programação em breve

Inscreva-se em Nossos Cursos

Inscrição em Cursos

Para informações, entre em contato

Localização

Rua Prof. Daher Cutait, 69
Bela Vista – São Paulo (SP)
CEP: 01308-060

Dúvidas e informações sobre os cursos

0800 730 2211